[The rational diagnostic of cholangiocarcinoma].
暂无分享,去创建一个
P. Dítě | T. Kupka | T. Jonszta | D. Czerný | J. Havelka | J. Dvořáčková | E. Geryk | A. Martínek | V. Hrabovský | M. Bojková | M. Uvírová | M. Rydlo | P. Klvaňa | V. Jelínková
[1] S. Pereira,et al. Update on the Management of Cholangiocarcinoma , 2014, Digestive Diseases.
[2] G. Gores,et al. Molecular Pathogenesis of Cholangiocarcinoma , 2014, Digestive Diseases.
[3] Ondřej Urban MUDr,et al. Cholangiopankreatoskopie pomocí SpyGlass TM direct visualization system: Seznámení s metodou a první vlastní zkušenosti , 2013 .
[4] S. Hattori,et al. Clinicopathologic Analysis of Combined Hepatocellular-Cholangiocarcinoma According to the Latest WHO Classification , 2013, The American journal of surgical pathology.
[5] H. Thomas,et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update , 2012, Gut.
[6] B. Petersen,et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). , 2011, Gastrointestinal endoscopy.
[7] G. Gores,et al. Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.
[8] H. El‐Serag,et al. Risk factors for cholangiocarcinoma , 2011, Hepatology.
[9] G. Gores,et al. New staging system and a registry for perihilar cholangiocarcinoma , 2011, Hepatology.
[10] M. Marini,et al. Magnetic resonance cholangiography: past, present and future: a review. , 2010, European review for medical and pharmacological sciences.
[11] H. Thomas,et al. Polychlorinated biphenyls in bile of patients with biliary tract cancer. , 2009, Chemosphere.
[12] K. Lindor,et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis , 2008, Hepatology.
[13] I. Endo,et al. Intrahepatic cholangiocarcinoma , 2014, Radiopaedia.org.
[14] Jae Seung Kim,et al. Clinical Role of 18F-FDG PET-CT in Suspected and Potentially Operable Cholangiocarcinoma: A Prospective Study Compared With Conventional Imaging , 2008, The American Journal of Gastroenterology.
[15] B. Petersen,et al. Prospective Evaluation of Advanced Molecular Markers and Imaging Techniques in Patients With Indeterminate Bile Duct Strictures , 2008, The American Journal of Gastroenterology.
[16] S. Taylor-Robinson,et al. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[17] B. Petersen,et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.
[18] P. Selby,et al. Circulating markers of biliary malignancy: opportunities in proteomics? , 2008, The Lancet. Oncology.
[19] J. Leblanc,et al. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. , 2006, Gastrointestinal endoscopy.
[20] B. Weynand,et al. Endoscopic ultrasound guided fine needle aspiration in biliary and pancreatic diseases: pitfalls and performances. , 2004, Acta gastro-enterologica Belgica.
[21] H. El‐Serag,et al. The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.
[22] K. McGlynn,et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.
[23] H. Thomas,et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document , 2002, Gut.
[24] A. Bergquist. Cholangiocarcinoma in primary sclerosing cholangitis , 2001 .
[25] H. Thomas,et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998 , 2001, Gut.
[26] T. Patel. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.
[27] G. Gores,et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis , 2000, American Journal of Gastroenterology.
[28] Å. Danielsson,et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. , 1999, Journal of hepatology.
[29] P. Hytiroglou,et al. Differential diagnosis of hepatocellular nodular lesions. , 1998, Seminars in diagnostic pathology.
[30] W. Palmas,et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. , 2012, Gastrointestinal endoscopy.
[31] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[32] H. Uhlig. Hepatologie , 2009, Kinder- und Jugendmedizin.
[33] F. Vleggaar,et al. High lifetime risk of cancer in primary sclerosing cholangitis. , 2009, Journal of hepatology.
[34] M. D'Angelica,et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. , 2008, Journal of the American College of Surgeons.
[35] G. Gores. Cholangiocarcinoma: Current concepts and insights , 2003, Hepatology.
[36] S. Hesse,et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. , 2001, Hepatology.
[37] G. Gores,et al. Hepatobiliary malignancy. , 1998, Clinics in liver disease.
[38] E. Fishman,et al. Intrahepatic cholangiocarcinoma: the role of imaging in detection and staging. , 1997, Critical reviews in diagnostic imaging.